DAE HWA PHARM CO., LTD
067080 | KO
Overview
Corporate Details
- ISIN(s):
- KR7067080002
- LEI:
- Country:
- South Korea
- Address:
- 강원도 횡성군 횡성읍 한우로 495, 횡성군
- Website:
- http://www.dhpharm.co.kr
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-19 00:00 |
Capital/Financing Update
주요사항보고서(교환사채권발행결정)
|
Korean | 34.5 KB | ||
| 2025-09-19 00:00 |
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
|
Korean | 31.8 KB | ||
| 2025-09-18 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 25.8 KB | ||
| 2025-08-20 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 158.8 KB | ||
| 2025-08-11 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 1.7 MB | ||
| 2025-08-06 00:00 |
Notice of Dividend Amount
현금ㆍ현물배당결정 (분기배당)
|
Korean | 8.3 KB | ||
| 2025-08-05 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.1 KB | ||
| 2025-07-22 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 158.8 KB | ||
| 2025-06-12 00:00 |
Notice of Dividend Amount
중간(분기)배당을위한주주명부폐쇄(기준일)결정
|
Korean | 5.4 KB | ||
| 2025-06-12 00:00 |
Related Party Transaction
[기재정정]타인에대한채무보증결정
|
Korean | 24.3 KB | ||
| 2025-06-12 00:00 |
Capital/Financing Update
[기재정정]타인에대한담보제공결정
|
Korean | 25.9 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 1.4 MB | ||
| 2025-04-29 00:00 |
Regulatory Filings
투자판단관련주요경영사항 (리포락셀액(파클리탁셀)의 품목허가사항 변경신청 (유방암 신규 적응증 추가를 위한 식품의약품안전…
|
Korean | 16.5 KB | ||
| 2025-04-23 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB | ||
| 2025-04-23 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB |
Automate Your Workflow. Get a real-time feed of all DAE HWA PHARM CO., LTD filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for DAE HWA PHARM CO., LTD
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for DAE HWA PHARM CO., LTD via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Develops topical skin treatments by reformulating drugs with a lipid-based delivery platform.
Sweden
LIPI
Sweden
LIPI
Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.
United States of America
LPCN
United States of America
LPCN
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America
LQDA
United States of America
LQDA
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
United States of America
LSTA
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
United States of America
LGVN
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Switzerland
LONN
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
United States of America
LYEL
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
United States of America
LYRA
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
Norway
LYTIX
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
Poland
MAB